Immunocore Files 8-K for Disclosure and Exhibits
Ticker: IMCR · Form: 8-K · Filed: May 31, 2024 · CIK: 1671927
| Field | Detail |
|---|---|
| Company | Immunocore Holdings PLC (IMCR) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing, regulatory
Related Tickers: IMCR
TL;DR
IMCR filed an 8-K on 5/31 for Reg FD disclosure and exhibits.
AI Summary
Immunocore Holdings plc filed an 8-K on May 31, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This filing indicates that Immunocore is providing updated information to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Immunocore Holdings plc (company) — Registrant
- May 31, 2024 (date) — Date of Report
FAQ
What specific information was disclosed under Regulation FD?
The filing does not specify the content of the Regulation FD disclosure.
What financial statements or exhibits were filed?
The filing indicates that financial statements and exhibits were filed, but their specific content is not detailed in this summary.
Is this filing related to a specific event or transaction?
The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits,' suggesting it's for ongoing reporting rather than a singular event.
What is Immunocore Holdings plc's primary business?
Immunocore Holdings plc is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
When was Immunocore Holdings plc incorporated?
Immunocore Holdings plc was incorporated in England and Wales.
Filing Stats: 700 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-05-31 16:21:44
Filing Documents
- ef20030354_8k.htm (8-K) — 35KB
- ef20030354_ex99-1.htm (EX-99.1) — 38KB
- image00026.jpg (GRAPHIC) — 3KB
- image00027.jpg (GRAPHIC) — 3KB
- image00028.jpg (GRAPHIC) — 3KB
- 0001140361-24-028366.txt ( ) — 235KB
- imcr-20240531.xsd (EX-101.SCH) — 4KB
- imcr-20240531_lab.xml (EX-101.LAB) — 21KB
- imcr-20240531_pre.xml (EX-101.PRE) — 16KB
- ef20030354_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On May 31, 2024, Immunocore Holdings plc (the "Company") issued a press release announcing updated data from the Company's Phase 1 clinical trial of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients. As disclosed in the press release, the Company is presenting such data at the 2024 American Society of Oncology (ASCO) Annual Meeting on May 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. As discussed in the press release, the Company will host a conference call and live audio webcast today, May 31, 2024 at 7:15 p.m., Eastern Time, to discuss the Phase 1 PRAME expansion data and the Company's Phase 3 registrational trial in cutaneous melanoma. The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the Company's website at www.immunocore.com/investors. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated May 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: May 31, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer